Federal Register / Vol. 69, No. 192 / Tuesday, October 5, 2004 / Notices 59603

Agenda: To review and evaluate grant 

applications. 

Place: Four Points by Sheraton Bethesda, 

8400 Wisconsin Avenue, Bethesda, MD 

20814. 

Contact Person: Michael M. Sveda, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5152, 

MSC 7842, Bethesda, MD 20892, 301–435–

3565, svedam@csr.nih.gov.

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group, 

Oral, Dental and Craniofacial Sciences Study 

Section. 

Date: October 26–27, 2004. 

Time: 8:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The River Inn, 924 25th Street, NW., 

Washington, DC 20037. 

Contact Person: J. Terrell, Hoffeld, DDS, 

PhD, Dental Officer, USPHS, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7816, Bethesda, MD 20892, 301–435–

1781, hoffeldt@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ZRG1 

EMNR–A 02: Member Conflict. 

Date: October 28, 2004. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Syed M. Amir, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6172, 

MSC 7892, Bethesda, MD 20892, (301) 435–

1043, amirs@csr.nih.gov.

Name of Committee: Health of the 

Population Integrated Review Group, 

Biostatistical Methods and Research Design 

Study Section. 

Date: October 29, 2004. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037. 

Contact Person: Ann Hardy, DRPH, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3158, 

MSC 7770, Bethesda, MD 20892, (301) 435–

0695, hardyan@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Social 

Science and Population Studies R03s, R15s, 

and R21s. 

Date: October 29, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: One Washington Circle Hotel, One 

Washington Circle, Washington, DC 20037.

Contact Person: Valerie Durrant, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3148, 

MSC 7770, Bethesda, MD 20892, (301) 435–

3554, durrantv@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Stem Cell 

Therapy and Ion Channels in the Heart. 

Date: October 29, 2004. 

Time: 10:30 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Four Points by Sheraton Bethesda, 

8400 Wisconsin Avenue, Bethesda, MD 

20814. 

Contact Person: Anshumali Chaudhari, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4124, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1210, chaudhaa@csr.nih.gov.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Microcirculation and Hypertension. 

Date: October 29, 2004. 

Time: 1:15 p.m. to 2:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Latham Hotel, 3000 M Street, NW., 

Washington, DC 20007. 

Contact Person: Robert T. Su, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4134, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1195, sur@csr.nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS)

Dated: September 28, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–22310 Filed 10–4–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Asthma Exacerbations: Biology and Disease 

Progression. 

Date: October 27, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Columbia Hotel, 10207 

Wincopin Circle, Columbia, MD 21044. 

Contact Person: Arthur N. Freed, PhD, 

Review Branch, Room 7186, Division of 

Extramural Affairs, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6701 Rockledge Drive, MSC 7924, Bethesda, 

MD 20892, (301) 435–0280.

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Review of Institutional National Research 

Service Award (T32) and Research Scientist 

Development Awards (K01s). 

Date: November 3, 2004. 

Time: 1 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Zoe Huang, MD, Health 

Scientist Administrator, Review Branch, 

Room 7190, Division of Extramural Affairs, 

National Heart, Lung, and Blood Institute, 

National Institutes of Health, 6701 Rockledge 

Drive, MSC 7924, Bethesda, MD 20892–7924, 

301–435–0314.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart, and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS)

Dated: September 28, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–22312 Filed 10–4–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

59604 Federal Register / Vol. 69, No. 192 / Tuesday, October 5, 2004 / Notices 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Member 

Conflict Meeting. 

Date: November 17, 2004. 

Time: 5 p.m. to 8 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Mark Swieter, PhD., 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, National Institutes of Health, 

DHHS, 6101 Executive Boulevard, Suite 220, 

Bethesda, MD 20892–8401, (301) 435–1389.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards, 93.278, Drug Abuse National 

Research Service Awards for Research 

Training, 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: September 28, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–22311 Filed 10–4–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines) 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

revised in the Federal Register on June 

9, 1994 (59 FR 29908) and on September 

30, 1997 (62 FR 51118). A notice listing 

all currently certified laboratories is 

published in the Federal Register

during the first week of each month. If 

any laboratory’s certification is 

suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

HHS National Laboratory Certification 

Program (NLCP) during the past month, 

it will be listed at the end, and will be 

omitted from the monthly listing 

thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov

and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; 240–276–2600 (voice), 240–276–

2610 (fax).

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines, 

‘‘Certification of Laboratories Engaged 

in Urine Drug Testing for Federal 

Agencies,’’ sets strict standards that 

laboratories must meet in order to 

conduct urine drug testing for Federal 

agencies. To become certified, an 

applicant laboratory must undergo three 

rounds of performance testing plus an 

on-site inspection. 

To maintain that certification, a 

laboratory must participate in a 

quarterly performance testing program 

plus periodic, on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements expressed in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines, the following 

laboratories meet the minimum 

standards set forth in the Mandatory 

Guidelines:

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328–

7840 / 800–877–7016, (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770 / 888–290–

1150. 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615–

255–2400. 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Rd., Lenexa, KS 66215–2802, 800–

445–6917. 

Diagnostic Services Inc., dba DSI, 12700 

Westlinks Dr., Fort Myers, FL 33913, 

239–561–8200 / 800–735–5416. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671–

2281. 

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229 

Madison St., Suite 500, Nordstrom 

Medical Tower, Seattle, WA 98104, 

206–386–2661 / 800–898–0180, 

(Formerly: Laboratory of Pathology of 

Seattle, Inc., DrugProof, Division of 

Laboratory of Pathology of Seattle, 

Inc.). 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Rd., Warminster, PA 18974, 

215–674–9310. 

Dynacare Kasper Medical Laboratories*, 

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, 780–451–

3702 / 800–661–9876. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Dr., Oxford, MS 38655, 662–236–

2609.

Express Analytical Labs, 3405 7th Ave., 

Suite 106, Marion, IA 52302, 319–

377–0500. 

General Medical Laboratories, 36 South 

Brooks St., Madison, WI 53715, 608–

267–6225. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, 504–

361–8989 / 800–433–3823, (Formerly: 

Laboratory Specialists, Inc.). 

LabOne, Inc., 10101 Renner Blvd., 

Lenexa, KS 66219, 913–888–3927 / 

800–873–8845, (Formerly: Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

LabOne, Inc., d/b/a Northwest 

Toxicology, 1141 E. 3900 S., Salt Lake 

City, UT 84124, 801–293–2300 / 800–

322–3361, (Formerly: NWT Drug 

Testing, NorthWest Toxicology, Inc.; 

Northwest Drug Testing, a division of 

NWT Inc.). 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Rd., 

Houston, TX 77040, 713–856–8288 / 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400 / 800–437–

4986, (Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Dr., 

Research Triangle Park, NC 27709, 

919–572–6900 / 800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche